Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model

Carcinogenesis

Volumn 35, Issue 2, 2014, Pages 415-423

  Khan, Naghma ^a   Bharali, Dhruba J ^b   Adhami, Vaqar M ^a   Siddiqui, Imtiaz A ^a   Cui, Huadong ^b   Shabana, Sameh M ^c   Mousa, Shaker A ^b   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c Mansoura University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CHITOSAN; CYCLINE; EPIGALLOCATECHIN GALLATE; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYPHENOL; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INTESTINE FLUID; LIGHT SCATTERING; MALE; MOUSE; NANOTECHNOLOGY; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; STOMACH JUICE; STOMACH PH; TEA; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTICARCINOGENIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CATECHIN; CELL PROLIFERATION; CHITOSAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, NUDE; NANOPARTICLES; NANOTECHNOLOGY; POLY(ADP-RIBOSE) POLYMERASES; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TEA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893393254     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt321     Document Type: Article

References (52)

1. Prasain,J.K. et al. (2007) Metabolism and bioavailability of flavonoids in chemoprevention: current analytical strategies and future prospectus. Mol. Pharm., 4, 846-864.
2. William,W.N. Jr et al. (2009) Molecular targets for cancer chemoprevention. Nat. Rev. Drug Discov., 8, 213-225.
3. Surh,Y.J. (2003) Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer, 3, 768-780.
4. Ferrari,M. (2005) Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer, 5, 161-171.
5. Siddiqui,I.A. et al. (2012) Impact of nanotechnology in cancer: emphasis on nanochemoprevention. Int. J. Nanomedicine, 7, 591-605.
6. Nie,S. et al. (2007) Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng., 9, 257-288.
7. Bharali,D.J. et al. (2011) Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. Cancers, 3, 4024-4045.
8. Huang,Q. et al. (2010) Bioavailability and delivery of nutraceuticals using nanotechnology. J. Food Sci., 75, R50-R57.
9. Karn,P.R. et al. (2011) Mucoadhesive liposomal delivery systems: the choice of coating material. Drug Dev. Ind. Pharm., 37, 482-488.
10. Ensign,L.M. et al. (2012) Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev., 64, 557-570.
11. Sun,M. et al. (2012) Advances in nanotechnology-based delivery systems for curcumin. Nanomedicine (Lond.), 7, 1085-1100.
12. Khan,N. et al. (2006) Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res., 66, 2500-2505.
13. Adhami,V.M. et al. (2007) Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res., 13, 1611-1619.
14. Siddiqui,I.A. et al. (2008) Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene, 27, 2055-2063.
15. Siddiqui,I.A. et al. (2009) Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res., 69, 1712-1716.
16. Siddiqui,I.A. et al. (2011) Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J., 25, 1198-1207.
17. Hastak,K. et al. (2005) Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J., 19, 789-791.
18. Khan,N. et al. (2013) Modulation of signaling pathways in prostate cancer by green tea polyphenols. Biochem. Pharmacol., 85, 667-672.
19. Zheng,J. et al. (2011) Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. Nutr. Cancer, 63, 663-672.
20. Boehm,K. et al. (2009) Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst. Rev., CD005004.
21. Bettuzzi,S. et al. (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res., 66, 1234-1240.
22. Brausi,M. et al. (2008) Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur. Urol., 54, 472-473.
23. Sanna,V. et al. (2011) Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells. J. Med. Chem., 54, 1321-1332.
24. Chow,H.H. et al. (2005) Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin. Cancer Res., 11, 4627-4633.
25. Takeuchi,H. et al. (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev., 47, 39-54.
26. Bowman,K. et al. (2006) Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomedicine, 1, 117-128.
27. Wang,J.J. et al. (2011) Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomedicine, 6, 765-774.
28. Jayaraman,M.S. et al. (2012) Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration. Mol. Vis., 18, 2300-2308.
29. Borchard,G. (2001) Chitosans for gene delivery. Adv. Drug Deliv. Rev., 52, 145-150.
30. Ray,S.D. (2011) Potential aspects of chitosan as pharmaceutical excipient. Acta Pol. Pharm., 68, 619-622.
31. Singla,A.K. et al. (2001) Chitosan: some pharmaceutical and biological aspects-an update. J. Pharm. Pharmacol., 53, 1047-1067.
32. Wedmore,I. et al. (2006) A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J. Trauma, 60, 655-658.
33. Porporatto,C. et al. (2009) The biocompatible polysaccharide chitosan enhances the oral tolerance to type II collagen. Clin. Exp. Immunol., 155, 79-87.
34. Khan,N. et al. (2008) A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res., 68, 8555-8563.
35. Khan,N. et al. (2012) Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo. Antioxid. Redox Signal., 16, 1195-1204.
36. Stamey,T.A. et al. (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 317, 909-916.
37. Rouleau,M. et al. (2010) PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer, 10, 293-301.
38. Finkel,E. (2001) The mitochondrion: is it central to apoptosis? Science, 292, 624-626.
39. Salvesen,G.S. (2002) Caspases and apoptosis. Essays Biochem., 38, 9-19.
40. Berney,D.M. et al. (2009) Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br. J. Cancer, 100, 888-893.
41. Folkman,J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1, 27-31.
42. Hasan,J. et al. (2002) Intra-tumoural microvessel density in human solid tumours. Br. J. Cancer, 86, 1566-1577.
43. McMahon,G. (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist, 5 (suppl. 1), 3-10.
44. Khan,N. et al. (2009) Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr. Cancer, 61, 836-841.
45. Khan,N. et al. (2008) Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid. Redox Signal., 10, 475-510.
46. Singh,S. et al. (2012) Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res., 72, 5663-5668.
47. Khan,N. et al. (2007) Tea polyphenols for health promotion. Life Sci., 81, 519-533.
48. Khan,N. et al. (2008) Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett., 269, 269-280.
49. Khan,N. et al. (2013) Tea and health: studies in humans. Curr. Pharm. Des., 19, 6141-6147.
50. Zhang,H. et al. (2012) Preparation and characterization of water-soluble chitosan nanoparticles as protein delivery system. J. Nanomater., 1, 1-5.
51. Gibson,B.A. et al. (2012) New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol., 13, 411-424.
52. Villanueva,T. (2010) Anticancer drugs: expanding the horizons of PARP inhibitors. Nat. Rev. Drug Discov., 9, 919.